These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31744894)

  • 1. Rational Combination Therapy for Melanoma with Dinaciclib by Targeting BAK-Dependent Cell Death.
    Xu X; Eshima S; Kato S; Fisher DE; Sakurai H; Hayakawa Y; Yokoyama S
    Mol Cancer Ther; 2020 Feb; 19(2):627-636. PubMed ID: 31744894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells.
    Buzzetti M; Morlando S; Solomos D; Mehmood A; Cox AWI; Chiesa M; D'Alessandra Y; Garofalo M; Topham CH; Di Leva G
    Sci Rep; 2021 Mar; 11(1):5374. PubMed ID: 33686114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
    Saqub H; Proetsch-Gugerbauer H; Bezrookove V; Nosrati M; Vaquero EM; de Semir D; Ice RJ; McAllister S; Soroceanu L; Kashani-Sabet M; Osorio R; Dar AA
    Sci Rep; 2020 Oct; 10(1):18489. PubMed ID: 33116269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
    Huang J; Chen P; Liu K; Liu J; Zhou B; Wu R; Peng Q; Liu ZX; Li C; Kroemer G; Lotze M; Zeh H; Kang R; Tang D
    Gut; 2021 May; 70(5):890-899. PubMed ID: 32816920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.
    Azimi A; Caramuta S; Seashore-Ludlow B; Boström J; Robinson JL; Edfors F; Tuominen R; Kemper K; Krijgsman O; Peeper DS; Nielsen J; Hansson J; Egyhazi Brage S; Altun M; Uhlen M; Maddalo G
    Mol Syst Biol; 2018 Mar; 14(3):e7858. PubMed ID: 29507054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic Anti Leukemia Effect of a Novel Hsp90 and a Pan Cyclin Dependent Kinase Inhibitors.
    Abdalla AN; Abdallah ME; Aslam A; Bader A; Vassallo A; Tommasi N; Malki WH; Gouda AM; Mukhtar MH; El-Readi MZ; Alkahtani HM; Abdel-Aziz AA; El-Azab AS
    Molecules; 2020 May; 25(9):. PubMed ID: 32397330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner.
    Varadarajan S; Poornima P; Milani M; Gowda K; Amin S; Wang HG; Cohen GM
    Oncotarget; 2015 May; 6(14):12668-81. PubMed ID: 26059440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
    Chen Y; Germano S; Clements C; Samuel J; Shelmani G; Jayne S; Dyer MJ; Macip S
    Br J Haematol; 2016 Nov; 175(4):641-651. PubMed ID: 27469405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
    Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
    Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells.
    Premkumar DR; Jane EP; Thambireddy S; Sutera PA; Cavaleri JM; Pollack IF
    Mol Carcinog; 2018 Apr; 57(4):469-482. PubMed ID: 29240261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK5 inhibition in vitro and in vivo induces cell death in myeloma and overcomes the obstacle of bortezomib resistance.
    Tang H; Xu L; Cen X; Yang L; Feng J; Li G; Zhu H; Gao S; Yu Y; Zhao Y; Tian Z; Hou L; Yu S; Gao G
    Int J Mol Med; 2020 Jun; 45(6):1661-1672. PubMed ID: 32236619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
    Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
    Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.
    Jane EP; Premkumar DR; Cavaleri JM; Sutera PA; Rajasekar T; Pollack IF
    J Pharmacol Exp Ther; 2016 Feb; 356(2):354-65. PubMed ID: 26585571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of Targeting VEGFR-2 and Cyclin D1 in Luminal-A Breast Cancer.
    Abdalla AN; Qattan A; Malki WH; Shahid I; Hossain MA; Ahmed M
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33050377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib.
    Hallaj S; Heydarzadeh Asl S; Alian F; Farshid S; Eshaghi FS; Namdar A; Atyabi F; Masjedi A; Hallaj T; Ghorbani A; Ghalamfarsa G; Sojoodi M; Jadidi-Niaragh F
    Life Sci; 2020 Oct; 259():118150. PubMed ID: 32726663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dinaciclib potently suppresses MCL-1 and selectively induces the cell death in human iPS cells without affecting the viability of cardiac tissue.
    Alsayegh K; Matsuura K; Sekine H; Shimizu T
    Sci Rep; 2017 Mar; 7():45577. PubMed ID: 28361959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway.
    Tsao AN; Chuang YS; Lin YC; Su Y; Chao TC
    Oncol Rep; 2022 May; 47(5):. PubMed ID: 35417031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling.
    Desai BM; Villanueva J; Nguyen TT; Lioni M; Xiao M; Kong J; Krepler C; Vultur A; Flaherty KT; Nathanson KL; Smalley KS; Herlyn M
    PLoS One; 2013; 8(3):e59588. PubMed ID: 23527225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
    Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
    Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAPK pathway inhibition enhances the efficacy of an anti-endothelin B receptor drug conjugate by inducing target expression in melanoma.
    Asundi J; Lacap JA; Clark S; Nannini M; Roth L; Polakis P
    Mol Cancer Ther; 2014 Jun; 13(6):1599-610. PubMed ID: 24651527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.